CYP19A1 and breast carcinoma: In breast cancer, overweight and obese patients have a poorer prognosis than patients with normal body weight, because of increased estrogen hormone levels in adipocytes and the decreased effects of aromatase inhibitors in breast cancer patients with a higher BMI3.